Ami Fadia: Thanks. Thanks for the question. My question is about Vision 2025. There’s a meaningful gap between the consensus and then your outlook for — can you talk to where you think you might be more confident in the performance of the business? And to what extent do you need to rely on future business development or new pipeline successes in order to be able to get to that $5 billion number? Thanks.
Bruce Cozadd: Yes. Hi, Ami, and thanks for the question. I would say that even when we first communicated Vision 2025, we talked about having revenues from our existing commercial portfolio, but also including a placeholder for productivity out of our pipeline and/or corp dev with a strong commitment to doing corp dev. And maybe Renee can make a few more comments about how we’re thinking about that.
Renée Galá: Sure. Yes, I’d be happy to. Well, Ami, as we look forward, we certainly expect corporate development to continue to be an important strategic pillar for us. Clearly, it had a huge impact on our ability to grow and diversify our revenues to date and also expand our pipeline. So as you look at the deal we just transacted on with Zanidatamab, it has the potential, as Bruce had mentioned, to contribute to Vision 2025 both as part of the $500 million placeholder we’ve identified from future growth in corporate development, but also as part of the five novel therapies to deliver by the end of the decade. As we look at that strategic framework for corporate development, we’re looking at early assets that have the opportunity to continue to grow that pipeline, but also late molecules and then things that can also be very close to commercial.
I’d put zani in that category in terms of being able to contribute to two different pillars. And we’re excited in the case of zanidatamab to be a potential best-in-class therapy. This is the sort of transaction for us that we think has the potential to have a meaningful impact for patients, where we can apply our unique insights, where we have the ability to commercialize efficiently given the overlap with Zepzelca. And we’ll continue to look at transactions of this nature. And then, I’ll just note, just given our financial position right now and the speed at which we’ve delevered the health of our operating cash flow, we feel confident in our ability to continue to leverage corporate developments. We, of course, as we look forward, see a lot of opportunities, still given valuations where they are today, and have a corporate development group that’s quite busy.
So we’re excited about the opportunity to continue to lean into that part of our business to augment what we have already as a business. We’re really excited about with the opportunities we have to grow the top line and continue to drive the pipeline forward with what we have in-house today.
Ami Fadia: Thank you.
Operator: Please stand by for our next question. Our next question comes from Ash Verma with UBS. Your line is open.
